USPTO serial 88744777
RING
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- ANDERSON, CASSONDRA CR
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RING?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi, Esq.
Christina M. Licursi, Esq. WOLF GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in the prevention, diagnosis and treatment of disease, namely, rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in gene therapy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 2, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 2, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 10, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 9, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Mar 9, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 24, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Feb 24, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 1, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 30, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 30, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 30, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 28, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 28, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 27, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 25, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 25, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 25, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 1, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 1, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 1, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 1, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 17, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 29, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 27, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 26, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 26, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 24, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 9, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |